Tech Digest

The 21st Century Cures Act Won’t Cure Our Healthcare Problems

Stay Up to Date!

Simply enter your email below and click SIGN UP!

From Bioscience Expert Patrick Cox - The Most Life-Changing Book You'll Read This Year - Click Here

December 5, 2016

Dear Reader,

Having passed the House with overwhelming support, the $6 billion 21st Century Cures Act is on track to become law. Its original purpose (before lobbyists spent more than $100 million to influence the legislation) was to accelerate the development and approval of new drugs and medical devices.

Faster regulatory approval would clearly aid patients who are denied access to unapproved treatments and cures. It would also heal the economy by addressing the rising cost of healthcare for the aged, which drives government spending and debt.

The CBO has explained the issue here, so I’ll just summarize. An increasingly older population means growing medical costs. This takes resources away from saving and investment, which create economic growth.

Former Fed Chair Alan Greenspan agrees with this assessment. He states that our employment and debt problems are not driven by bad economic policies. Rather, they’re the result of “age and health and the like.”

Research isn’t the answer

The problems of “age and health and the like” are solvable. But the Cure Act won’t be enough to do it. Why? Because it doesn’t clear the logjam holding back innovation. Rather, most of the money ($4.8 billion) would fund research into key areas. This includes stem cell or regenerative medicine. I’m generally in favor of increased research spending, but that’s not where our current focus should be.

We already have cures. The last two decades have seen more biological discovery than all those in previous history. In fact, many world-changing biotechnologies are already licensed to startups, but most of them are limping toward commercialization in a process that can take more than a decade.

Due to high regulatory barriers, drug development typically costs tens of millions of dollars in the early stages. Phase 3 trials cost even more. I’ll give you a good example.

Perhaps the most dramatic medical news in recent years came from Asterias Biotherapeutics. For the first time ever, quadriplegics with catastrophic spinal cord injury have had significant control and sensation restored. Moreover, these results occurred in the first three months of a 12-month trial using partial doses of genetically modified stem cells.

You might be surprised to learn that this isn’t even a 21st century technology. Michael West PhD created this therapy 20 years ago at Geron, the company he founded. But Geron was so ground down by the effort to move this cure to market, the board gave up. Later, West reacquired the rights to his breakthrough for BioTime (*see disclosure below). He then created a subsidiary, Asterias Biotherapeutics, to take the technology into trials.

Reforming the drug development process

Over the past 20 years, West has pushed the science of regenerative medicine much further. In fact, the embryonic stem cells used in West’s revolutionary spinal cord therapy are, according to him, now obsolete. But regulators won’t allow the use of non-embryonic pluripotent stem cells without a lengthy and costly approval process. West also seems to have applied for a patent on a biotechnology that would repair older spinal cord injuries as well as damaged organs and limbs. These are important breakthroughs that exist right now.

So why would we spend billions of dollars on pure research, including stem cell medicine, when a private company is decades ahead of academic researchers? It makes no sense.

The government of Japan knows this. Japanese law permits regenerative medicine procedures in patients after proving safety. That process might take only a few million dollars and six months. This allows companies to skip phase 2 and 3 trials, which account for most of the cost and delay associated with drug development. Instead, they can move from phase 1 to phase 4 (tracking and publishing results in real patients).

This is the real model for regulatory reform. If we truly want to speed up the development and approval of new drugs and medical devices, that’s how we should do it.

So where did the Japanese get the idea? They got it from Andrew von Eschenbach, former commissioner of the FDA. You can read more about his ideas here.

We live in very exciting times, and there’s a good chance we might see a shift to more de-regulation here in the US too. In my Transformational Technology Alert, my team and I closely follow these revolutionary developments and show you how to profit from the companies’ success.

That reminds me that until December 13, you can get my premium alert service plus five other excellent Mauldin Economics services for one low price by becoming a Mauldin VIP. Subscribing to this Six-in-One offer can save you thousands of dollars, and you’ll receive a weekly summary of all the buy and sell recommendations for a quick and easy overview. Click here for more information.

(*Disclosure: The editors or principals of Mauldin Economics have a position in this security. They have no plans to sell their position at this time. There is an ethics policy in place that specifies subscribers must receive advance notice should the editors or principals intend to sell.)

Sincerely,
Patrick Cox
Patrick Cox
Editor, Transformational Technology Alert

Mauldin Economics

 

Stay in the Loop on Life-Extending Research
with Patrick Cox's Tech Digest

Tech Digest


Your privacy is very important to us. Please review our Privacy Policy.

Tags:

« Back to Articles

From Bioscience Expert Patrick Cox - The Most Life-Changing Book You'll Read This Year - Click Here

Discuss This

We welcome your comments. Please comply with our Community Rules.

Comments

There are no comments at this time.


Use of this content, the Mauldin Economics website, and related sites and applications is provided under the Mauldin Economics Terms & Conditions of Use.

Unauthorized Disclosure Prohibited

The information provided in this publication is private, privileged, and confidential information, licensed for your sole individual use as a subscriber. Mauldin Economics reserves all rights to the content of this publication and related materials. Forwarding, copying, disseminating, or distributing this report in whole or in part, including substantial quotation of any portion the publication or any release of specific investment recommendations, is strictly prohibited.
Participation in such activity is grounds for immediate termination of all subscriptions of registered subscribers deemed to be involved at Mauldin Economics’ sole discretion, may violate the copyright laws of the United States, and may subject the violator to legal prosecution. Mauldin Economics reserves the right to monitor the use of this publication without disclosure by any electronic means it deems necessary and may change those means without notice at any time. If you have received this publication and are not the intended subscriber, please contact service@mauldineconomics.com.

Disclaimers

The Mauldin Economics website, Yield Shark, Thoughts from the Frontline, Patrick Cox’s Tech Digest, Outside the Box, Over My Shoulder, World Money Analyst, Street Freak, Just One Trade, Transformational Technology Alert, Rational Bear, The 10th Man, Connecting the Dots, This Week in Geopolitics, Stray Reflections, and Conversations are published by Mauldin Economics, LLC. Information contained in such publications is obtained from sources believed to be reliable, but its accuracy cannot be guaranteed. The information contained in such publications is not intended to constitute individual investment advice and is not designed to meet your personal financial situation. The opinions expressed in such publications are those of the publisher and are subject to change without notice. The information in such publications may become outdated and there is no obligation to update any such information. You are advised to discuss with your financial advisers your investment options and whether any investment is suitable for your specific needs prior to making any investments.
John Mauldin, Mauldin Economics, LLC and other entities in which he has an interest, employees, officers, family, and associates may from time to time have positions in the securities or commodities covered in these publications or web site. Corporate policies are in effect that attempt to avoid potential conflicts of interest and resolve conflicts of interest that do arise in a timely fashion.
Mauldin Economics, LLC reserves the right to cancel any subscription at any time, and if it does so it will promptly refund to the subscriber the amount of the subscription payment previously received relating to the remaining subscription period. Cancellation of a subscription may result from any unauthorized use or reproduction or rebroadcast of any Mauldin Economics publication or website, any infringement or misappropriation of Mauldin Economics, LLC’s proprietary rights, or any other reason determined in the sole discretion of Mauldin Economics, LLC.

Affiliate Notice

Mauldin Economics has affiliate agreements in place that may include fee sharing. If you have a website or newsletter and would like to be considered for inclusion in the Mauldin Economics affiliate program, please go to http://affiliates.ggcpublishing.com/. Likewise, from time to time Mauldin Economics may engage in affiliate programs offered by other companies, though corporate policy firmly dictates that such agreements will have no influence on any product or service recommendations, nor alter the pricing that would otherwise be available in absence of such an agreement. As always, it is important that you do your own due diligence before transacting any business with any firm, for any product or service.

© Copyright 2017 Mauldin Economics